Opioid Substitution and Maintenance Treatment for Opioid Dependence

What this article is about

In a hypothetical situation, someone receives prescribed treatment, spends less time seeking illicit opioids, and returns to work and relationships. Yet they hear: “You have just replaced one drug with another.” This combines different questions: what the medicine does, why it is prescribed, what its risks are, and whether life is changing. Judging treatment only by whether an opioid remains part of it is insufficient.

This article explains maintenance treatment for opioid use disorder, how it differs from withdrawal management alone, and how to discuss its results. If you already receive treatment and are considering stopping because of pressure or doubts, speak to your prescriber first. Do not change treatment yourself on the basis of this article. Breathing difficulties or loss of consciousness require immediate help from your local emergency medical service. WHO: Opioid overdose.

What “substitution” and “maintenance” mean

Opioid use disorder can involve impaired control, increasing priority given to opioid use, and continuing despite harm. English clinical materials use the term opioid use disorder, or OUD. A diagnosis and physical adaptation to a medicine need to be distinguished: they answer different questions.

Methadone and buprenorphine are used in maintenance treatment for opioid dependence. They act on opioid receptors and can reduce craving and withdrawal symptoms. The purpose is more than changing the name of the substance on a list: it is to reduce dangerous non-medical use and the harm associated with it. WHO: Treatment options, CDC: Opioid Use Disorder — Treating.

“Maintenance” means continuing treatment to sustain its effect; it does not have to end as soon as withdrawal symptoms settle. The NHS distinguishes long-term methadone maintenance from detoxification followed by stopping the medicine. These are different care pathways, not two names for the same procedure. NHS: About methadone.

Medicines differ, and a name does not determine the treatment choice

Methadone is a full opioid receptor agonist: it activates the receptors. Buprenorphine is a partial agonist and works differently. Both can be used for OUD, but selecting a medicine and formulation, starting it, and managing treatment require medical assessment. They are not interchangeable at a reader's discretion. CDC: Medicines for OUD.

Naltrexone belongs to another category: an opioid receptor antagonist that blocks opioid effects. It can also be used for OUD, but is not agonist substitution treatment. Starting it requires specifically assessed clinical conditions; this article does not offer a way to switch independently or calculate a necessary interval. The options should not be presented as equally suitable for everyone.

Naltrexone should also not be confused with naloxone, which is used to reverse opioid effects in an overdose emergency. Receiving maintenance treatment does not remove the need to discuss overdose prevention, local access to naloxone, and training in its use with your care team. This is a separate safety task. CDC: Additional care.

Physical dependence is real, but does not mean recovery has failed

The body can adapt to an opioid medicine taken regularly. Symptoms when it is stopped or reduced should not be dismissed as imaginary; they matter when planning changes. At the same time, adaptation alone does not prove that prescribed treatment is equivalent to uncontrolled use.

The CDC's explanation of DSM-5 criteria includes an important caveat: tolerance and withdrawal are not counted as those diagnostic criteria when someone takes opioids solely under appropriate medical supervision. This does not mean that having a prescription rules out OUD or makes any use safe. Assessment considers the other signs, the history, and actual behaviour; medical supervision must be real. CDC: Opioid Use Disorder — Diagnosis.

For someone with an established OUD diagnosis, continuing treatment does not prove that the disorder never existed, nor determine their current condition without assessment. Likewise, physical adaptation during treatment does not erase progress. Diagnosis, the medicine's effects, and changes in behaviour are distinct issues.

Why detoxification alone may be insufficient

Withdrawal management helps with a particular stage, but does not address the whole task of treating OUD. The CDC does not recommend detoxification without medication treatment for OUD as the only care: it is associated with increased risks of returning to use, overdose, and death from overdose. CDC: Limits of detoxification.

Tolerance can change after a period without opioids; returning to previous non-medical use carries a risk of overdose. WHO specifically includes resuming use after abstinence, detoxification, or stopping treatment among risk factors. This is not an argument against wanting to stop non-medical use. It is a reason to discuss how to sustain progress and safety beforehand, rather than treating the end of withdrawal as the end of care. WHO: Risk factors.

The success of one short procedure cannot guarantee the future. Nor should someone have to go through a dangerous experiment on their own to “earn” maintenance care.

Duration is assessed in relation to the clinical task

The CDC's 2022 guideline has no recommended duration limit for OUD treatment with buprenorphine or methadone; discontinuation is associated with risks of returning to use and overdose. This provision about OUD must not be replaced with duration or dose limits intended for pain treatment. CDC MMWR: OUD treatment recommendations.

The absence of a general limit does not mean that everyone must receive one medicine for life or that review is unnecessary. Review matters when effects, health, risks, circumstances, and the person's goals change. Wanting to reduce treatment can be discussed; stopping should not become compulsory proof of being “clean.”

A planned change involves shared decisions and support. The clinician discusses the benefits of continuing, the risks of changing, and support afterwards. This article does not set a course length or a discontinuation schedule. When treatment helps someone live more safely, its duration alone does not make the result worse.

Which results to discuss

The CDC associates medication treatment for OUD with reduced overdose risk and overall mortality. WHO also describes benefits of maintenance treatment in reducing non-medical use, retaining people in care, and improving wellbeing. These are findings about groups receiving treatment, not a promise that an individual will be free of every risk. CDC: Treatment outcomes, WHO: Continuity of maintenance care.

For a conversation, compare life before and during treatment:

• Use and craving. Changes in non-medical use, searching for substances, and the ability to seek help when craving increases.
• Safety. Overdoses, dangerous drowsiness, or risky combinations of substances; whether a response plan has been agreed.
• Daily life. Sleep, work, self-care, relationships, and the ability to do necessary tasks.
• Tolerability. Side effects and other difficulties that need to be reported to a professional.
• Access and continuity. Whether treatment is available without unexpected interruptions and whether attendance is difficult.
• Personal goals. Which changes the person considers important and what is obstructing them now.

This is editorial preparation for a conversation, not a clinical effectiveness scale. One test result or one good week does not describe the whole outcome. If improvement is incomplete, obstacles need to be clarified and care reviewed, rather than automatically concluding that the person “does not want to recover.”

It helps to distinguish what you expect from the medicine from what requires other kinds of help. For example, reduced craving can be a meaningful result even while housing remains unresolved. But pronounced drowsiness should not be treated as an acceptable price for stability: report it to the clinician, and use emergency care if there are signs of an acute threat.

Benefits do not remove risks

Methadone and buprenorphine remain medicines that require appropriate prescribing and monitoring. Combining opioids with alcohol, benzodiazepines, and other substances that suppress breathing increases danger. Tell the team about all prescribed and non-prescribed substances, including sleeping medicines and anything taken for anxiety. WHO: Combinations and overdose, NHS: Methadone and alcohol.

However, the CDC specifically states that buprenorphine or methadone for OUD should not automatically be withheld simply because someone takes benzodiazepines or other medicines that depress the central nervous system. The risks of a combination and of untreated OUD need to be considered together. This requires medical management, not a choice at home between “leaving everything as it is” and suddenly stopping several medicines. CDC MMWR: Combinations during OUD treatment.

Do not conceal ongoing use because you fear losing care. The CDC notes that it may require greater support. The discussion should clarify risks and needs. Severe drowsiness, especially with impaired breathing or consciousness, calls for immediate medical assessment through emergency care rather than waiting for the next routine visit.

Interruptions and changes need separate attention

If treatment may be interrupted by moving, hospital admission, finances, or service problems, contact the team beforehand where possible. Ask about a lawful local route for continuing care and who to contact if access stops. Do not compensate for a gap by choosing another opioid yourself or restarting an old regimen without agreement.

WHO's 2025 materials stress the need for continuity and early action on disruptions. This is a requirement for healthcare organisation, not a claim that a medicine is readily available in every country. An unplanned interruption calls for support; a lack of services should not be reduced to a patient's lack of motivation. WHO: Maintaining services during disruption.

If you want to stop because of side effects or personal goals, tell the professional directly. Discussing a problem is part of treatment. A decision should not rest solely on shame about receiving medical care or comparison with somebody else's story.

Supporting life around treatment

A medicine does not automatically solve problems with housing, loneliness, debt, traumatic experiences, or relationships. The CDC recommends assessing psychosocial needs and offering appropriate care. At the same time, the absence of available psychological treatment, or a person's decision to decline it, should not prevent or delay OUD medication. CDC: Additional needs.

There should therefore be no condition that someone must “become completely motivated and sort out their whole life first.” Health can be supported while other foundations are gradually built. Psychological work, a safe environment, relationships, and meaning in life can be part of that process; they do not replace necessary medical treatment.

Someone close to the person can help with accessing care, everyday agreements, and understanding goals. They should not manage prescriptions themselves or require discontinuation as proof of love and trust. Protecting their own boundaries is compatible with respecting the other person's treatment.

What to prepare for the next appointment

Bring the information you have: what treatment you receive and from whom; changes in craving and non-medical use; side effects that trouble you; other substances or medicines you take; any interruptions; and goals you want to discuss. You do not need a perfect report before saying that something is wrong.

Ask how the team assesses benefits and risks, when treatment is reviewed, where to turn if things worsen or access is lost, and which overdose-prevention measures are available to you and people close to you. Finding care requires a practitioner or service that actually treats OUD in your jurisdiction. Authorisation of medicines, prescribing rules, cost, and monitoring arrangements vary; an English or Thai version of this article does not confirm local availability.

Recovery can be assessed through reduced harm and greater opportunities to live. Prescribed maintenance treatment can be part of that result. Continuing, changing, and possibly stopping it require a specific clinical discussion, rather than a moral examination.

Sources and basis

1. World Health Organization. Opioid overdose. Fact sheet, 29 August 2025: dependence, maintenance treatment, risk factors, and overdose prevention.
2. CDC. Opioid Use Disorder: Treating. Clinical explanation, 9 April 2024: medicines, outcomes, and the limits of detoxification.
3. NHS. About methadone. Public information; page reviewed 9 July 2025: maintenance care, withdrawal, and safety.
4. CDC. Opioid Use Disorder: Diagnosis. Clinical explanation, 16 April 2024: OUD and the tolerance/withdrawal caveat under appropriate medical supervision.
5. CDC. Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022. OUD provisions in recommendations 11–12 are used; pain-treatment provisions are not treated as a general maintenance regimen.
6. World Health Organization. WHO’s new guidance on maintaining opioid agonist maintenance treatment as an essential health service. Official update, 16 December 2025, on benefits and continuity of care; not the full guidance document.

Topic tags

Opioid use disorder; maintenance treatment; methadone; buprenorphine; physical dependence; detoxification; harm reduction; treatment outcomes; recovery.

About the authors

Andrey Zarinsh is the author and founder of United Wisdom. He explores inner transformation, the unity of traditions, intercultural dialogue, and contemporary spiritual discipline. Instagram: @andrey.zarinsh.

Maria Evilkut is a co-author of United Wisdom. Alongside her research, she seeks to test these ideas in practice and observe how principles of unity and mutual understanding work in real life between people and cultures. Instagram: @ilkutki.

Content reviewed: 13 October 2026. Language version: English.